Treating hepatitis C virus in patients with decompensated cirrhosis: Why is it so difficult and does a sustained response rate rescue the patient from liver transplantation?

Clinical Liver Disease

Volumn 6, Issue 6, 2015, Pages 133-135

  Kwo, Paul ^a   Agrawal, Saurabh ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; DACLATASVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; SOFOSBUVIR;

ANTIVIRAL THERAPY; AREA UNDER THE CURVE; CHILD PUGH SCORE; DECOMPENSATED LIVER CIRRHOSIS; DRUG LIVER LEVEL; DRUG RESPONSE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LIVER TRANSPLANTATION; LOW DRUG DOSE; MODEL FOR END STAGE LIVER DISEASE SCORE; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; SUSTAINED RESPONSE RATE;

EID: 84955269914     PISSN: None     EISSN: 20462484     Source Type: Journal    
DOI: 10.1002/cld.519     Document Type: Review

References (14)

1. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105-114.
2. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-587.
3. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
4. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
5. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649-659.
6. Manns M, Forns X, Samuel D, Denning J, Arterburn S, Brandt-Sarif T, et al. G02: ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the prospective solar 2 trial. J Hepatol 2015;62:S187-S188.
7. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. LO8: Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study. J Hepatol 2015;62:S261-S262.
8. Foster G, McLauchlan J, Irving W, Cheung M, Hudson B, Verma S, et al. O002: Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3. J Hepatol 2015;62:S190-S191.
9. Babusis DM, Curry MP, Denning J, Park Y, Murakami E, Afdhal N, et al. Nucleotide analog levels in liver explants from HCV infected subjects undergoing liver transplantation after up to 24 weeks sofosbuvir (GS-7977) with ribavirin treatment. Hepatology 2013;58:111.
10. Lens S, Rincón D, García-Retortillo M, Albillos A, Calleja JL, Bañares R, et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol 2015;13:1846-1853.
11. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-1982.
12. Bourlière MJ-PB, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, Tran A, et al. Ledipasvir/Sofosbuvir fixed-dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy. Hepatology 2014;60:1270A.
13. Afdhal N, Everson GT, Calleja JL, McCaughan G, Bosch J, Denning J . LP13: Effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. J Hepatol 2015;62(suppl 2):S269-S270.
14. Reddy R, Lim JK, Kuo A, Di Bisceglie AM, Vargas HM, Galati JS, et al. O007: All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: interim report from the HCV-target real world experience. J Hepatol 2015;62:S193.